Founded by two neuroscientists, NeuroKaire says its novel, AI-assisted tech uses stem cells to create a brain proxy against ...
A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and ...
Depression is a heterogeneous mental illness with substantial personal and societal burdens, yet its diagnosis still relies heavily on subjective assessments. Recent advances in blood-based ...
Zacks Investment Research on MSN
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
The funding includes €2 million ($2.35 million) in seed investment from Critical Path Ventures and €1 million ($1.18 million) ...
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback